Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53

被引：0
|
作者：
Phong Lu
Erica R. Vander Mause
Katherine E. Redd Bowman
Sarah M. Brown
Lisa Ahne
Carol S. Lim
机构：
[1] University of Utah,Department of Pharmaceutics and Pharmaceutical Chemistry
[2] Philipps-Universitat Marburg,undefined
来源：
Journal of Ovarian Research | / 12卷
关键词：
p53; BakMTS; BaxMTS; DBD; Dominant negative; Apoptosis; Mitochondria; Ovarian cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Mitochondrially targeted p53 or DBD subdomain is superior to wild type p53 in ovarian cancer cells even with strong dominant negative mutant p53
    Lu, Phong
    Vander Mause, Erica R.
    Bowman, Katherine E. Redd
    Brown, Sarah M.
    Ahne, Lisa
    Lim, Carol S.
    JOURNAL OF OVARIAN RESEARCH, 2019, 12 (1)
  • [2] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    Palacios, G.
    Moll, U. M.
    ONCOGENE, 2006, 25 (45) : 6133 - 6139
  • [3] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    G Palacios
    U M Moll
    Oncogene, 2006, 25 : 6133 - 6139
  • [4] p53 tetramerization: at the center of the dominant-negative effect of mutant p53
    Gencel-Augusto, Jovanka
    Lozano, Guillermina
    GENES & DEVELOPMENT, 2020, 34 (17-18) : 1128 - 1146
  • [5] Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function
    de Vries, A
    Flores, ER
    Miranda, B
    Hsieh, HM
    van Oostrom, CTM
    Sage, J
    Jacks, T
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (05) : 2948 - 2953
  • [6] Impact of p53 on the occurrence of autophagy in p53 mutant U138 cells and wild type p53 U87 cells
    Johnson, Cassi
    Wetmore, Lori A.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2012, 243
  • [7] Preclinical evaluation of a radiosensitizing effect of gemcitabine in p53 mutant and p53 wild type bladder cancer cells
    Fechner, G
    Perabo, FGE
    Schmidt, DH
    Haase, L
    Ludwig, E
    Schueller, H
    Blatter, J
    Müller, SC
    Albers, P
    UROLOGY, 2003, 61 (02) : 468 - 473
  • [8] Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation
    De Smet, Frederik
    Rubio, Mirian Saiz
    Hompes, Daphne
    Naus, Evelyne
    De Baets, Greet
    Langenberg, Tobias
    Hipp, Mark S.
    Houben, Bert
    Claes, Filip
    Charbonneau, Sarah
    Blanco, Javier Delgado
    Plaisance, Stephane
    Ramkissoon, Shakti
    Ramkissoon, Lori
    Simons, Colinda
    van den Brandt, Piet
    Weijenberg, Matty
    Van England, Manon
    Lambrechts, Sandrina
    Amant, Frederic
    D'Hoore, Andre
    Ligon, Keith L.
    Sagaert, Xavier
    Schymkowitz, Joost
    Rousseau, Frederic
    JOURNAL OF PATHOLOGY, 2017, 242 (01): : 24 - 38
  • [9] p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
    Jean-Christophe Bourdon
    Marie P Khoury
    Alexandra Diot
    Lee Baker
    Kenneth Fernandes
    Mustapha Aoubala
    Philip Quinlan
    Colin A Purdie
    Lee B Jordan
    Anne-Catherine Prats
    David P Lane
    Alastair M Thompson
    Breast Cancer Research, 13
  • [10] p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients
    Bourdon, Jean-Christophe
    Khoury, Marie P.
    Diot, Alexandra
    Baker, Lee
    Fernandes, Kenneth
    Aoubala, Mustapha
    Quinlan, Philip
    Purdie, Colin A.
    Jordan, Lee B.
    Prats, Anne-Catherine
    Lane, David P.
    Thompson, Alastair M.
    BREAST CANCER RESEARCH, 2011, 13 (01):
12345